Key facts
- Veminsyn Biotech’s last known valuation is $89.7M (May 2025).
- It has raised $35.7M; the latest was Early Stage VC in Sep 2025.
- Notable investors include ZhenFund, Huatai Zijin Investment, HaiBang Ventures, Hangzhou Capital, CITIC Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Veminsyn Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Veminsyn Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Veminsyn Biotech
Developer of synthetic biology-based active ingredients intended for cosmetic and personal care applications. The company offers protein engineering, plant cell bioreactor systems, and high-throughput screening technologies to produce novel bioactive compounds, serving the skincare and beauty market to access domestically developed ingredient alternatives that support anti-aging, enhance skin health, and expand formulation possibilities through scalable and customizable biomanufacturing.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Employees
- 104
- Website
- veminsyn.com/
- Ownership
- Privately Held (backing)
Veminsyn Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Veminsyn Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Veminsyn Biotech in its N-PORT filings yet. We sweep new filings monthly.